Loading
Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval.
Nikhil Munshi was principal investigator of KarMMa, the pivotal trial showing the BCMA-directed CAR-T idecabtagene vicleucel produces responses in nearly three-quarters of heavily pretreated myeloma patients, leading to the first CAR-T approval in the disease, and of KarMMa-3 comparing it with standard regimens. His laboratory studies myeloma genomics and he led the meta-analysis establishing MRD negativity as a surrogate for survival.
| Title | Journal | Year |
|---|---|---|
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma (KarMMa) | NEJM | 2021 |
| Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis | JAMA Oncology | 2017 |
| KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma | New England Journal of Medicine | 2023 |
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares KarMMa-3, KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, CAR-T cell therapy.
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.